Details of the Drug

General Information of Drug (ID: DMT5GNL)

Drug Name

Romidepsin

Synonyms

Chromadax; Istodax; Antibiotic FR 901228; FK 228; FK228; FR 901228; FR901228; HDInhib_000006; Chromadax (TN); FK-228; FK-901228; FR-901228; Istodax (TN); Romidepsin (USAN); Cyclo((2Z)-2-amino-2-butenoyl-L-valyl-(3S,4E)-3-hydroxy-7-mercapto-4-heptenoyl-D-valyl-D-cysteinyl), cyclic (35)-disulfide; L-Valine, N-((3S,4E)-3-hydroxy-7-mercapto-1-oxo-4-heptenyl)-D-valyl-D-cysteinyl-(2Z)-2-amino-2-butenoxyl-, (4-1)-lactone, cyclic (1-2)-disulfide; (1S,4S,7Z,10S,16E,21R)-7-Ethylidene-4,21-bis(1-methylethyl)-2-oxa-12,13-dithia-5,8,20,23-tetraazabicyclo(8.7.6)tricos-16-ene-3,6,9,19,22-pentone; (1S,4S,7Z,10S,16E,21R)-7-ethylidene-4,21-di(propan-2-yl)-2-oxa-12,13-dithia-5,8,20,23-tetraazabicyclo[8.7.6]tricos-16-ene-3,6,9,19,22-pentone; (1S,4S,7Z,10S,16E,21R)-7-ethylidene-4,21-di(propan-2-yl)-2-oxa-12,13-dithia-5,8,20,23-tetrazabicyclo[8.7.6]tricos-16-ene-3,6,9,19,22-pentone

Indication

Disease Entry	ICD 11	Status	REF
Cutaneous T-cell lymphoma	2B01	Approved	[1]
Gastrin-producing neuroendocrine tumor	N.A.	Approved	[2]
Glucagonoma	N.A.	Approved	[2]
Insulinoma	2C10.1	Approved	[2]
Lung carcinoid tumor	N.A.	Approved	[2]
Melanoma	2C30	Approved	[2]
Primary cutaneous peripheral T-cell lymphoma not otherwise specified	N.A.	Approved	[2]
Primary cutaneous T-cell lymphoma	N.A.	Approved	[2]
Urethral cancer	2C93	Approved	[2]
Peripheral T-cell lymphoma	2A90.C	Phase 3	[3]
Renal cell carcinoma	2C90	Phase 3	[1]
------------------------------------------------------------------------------------


⏷ Show the Full List of Indication(s)

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

#Ro5 Violations (Lipinski): 1

Molecular Weight (mw)

540.7

Logarithm of the Partition Coefficient (xlogp)

2.2

Rotatable Bond Count (rotbonds)

Hydrogen Bond Donor Count (hbonddonor)

Hydrogen Bond Acceptor Count (hbondacc)

ADMET Property

BDDCS Class: Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 2: low solubility and high permeability [4]
Clearance: The clearance of drug is 8.4 L/h []
Half-life: The concentration or amount of drug in body reduced by one-half in 3 hours [5]
Metabolism: The drug is metabolized via the hepatic []
MRTD: The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 0.64 micromolar/kg/day [6]
Unbound Fraction: The unbound fraction of drug in plasma is 0.07% [5]
Vd: The volume of distribution (Vd) of drug is 44.5 L []

Chemical Identifiers

Formula: C24H36N4O6S2
IUPAC Name: (1S,4S,7Z,10S,16E,21R)-7-ethylidene-4,21-di(propan-2-yl)-2-oxa-12,13-dithia-5,8,20,23-tetrazabicyclo[8.7.6]tricos-16-ene-3,6,9,19,22-pentone
Canonical SMILES: C/C=C\\1/C(=O)N[C@H](C(=O)O[C@H]\\2CC(=O)N[C@@H](C(=O)N[C@H](CSSCC/C=C2)C(=O)N1)C(C)C)C(C)C
InChI: InChI=1S/C24H36N4O6S2/c1-6-16-21(30)28-20(14(4)5)24(33)34-15-9-7-8-10-35-36-12-17(22(31)25-16)26-23(32)19(13(2)3)27-18(29)11-15/h6-7,9,13-15,17,19-20H,8,10-12H2,1-5H3,(H,25,31)(H,26,32)(H,27,29)(H,28,30)/b9-7+,16-6-/t15-,17-,19-,20+/m1/s1
InChIKey: OHRURASPPZQGQM-GCCNXGTGSA-N

Cross-matching ID

PubChem CID: 5352062
ChEBI ID: CHEBI:61080
CAS Number: 128517-07-7
DrugBank ID: DB06176
TTD ID: D0L7LC
VARIDT ID: DR00233
INTEDE ID: DR1438
ACDINA ID: D01401

Combinatorial Drugs (CBD)

Click to Jump to the Detailed CBD Information of This Drug

Repurposed Drugs (RPD)

Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Histone deacetylase 1 (HDAC1)	TT6R7JZ	HDAC1_HUMAN	Inhibitor	[7]

------------------------------------------------------------------------------------

Drug Transporter (DTP)

DTP Name	DTP ID	UniProt ID	MOA	REF
Organic anion transporting polypeptide 1B3 (SLCO1B3)	DT9C1TS	SO1B3_HUMAN	Substrate	[8]
P-glycoprotein 1 (ABCB1)	DTUGYRD	MDR1_HUMAN	Substrate	[8]

------------------------------------------------------------------------------------

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 3A4 (CYP3A4)_{Main DME}	DE4LYSA	CP3A4_HUMAN	Substrate	[9]
Cytochrome P450 3A5 (CYP3A5)	DEIBDNY	CP3A5_HUMAN	Substrate	[10]
Cytochrome P450 2B6 (CYP2B6)	DEPKLMQ	CP2B6_HUMAN	Substrate	[11]

------------------------------------------------------------------------------------

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
ATP-dependent translocase ABCB1 (ABCB1)	OTEJROBO	MDR1_HUMAN	Gene/Protein Processing	[12]
Bcl-2 homologous antagonist/killer (BAK1)	OTDP6ILW	BAK_HUMAN	Gene/Protein Processing	[13]
Bcl-2-interacting killer (BIK)	OTTH1T3D	BIK_HUMAN	Gene/Protein Processing	[14]
Bcl-2-like protein 11 (BCL2L11)	OTNQQWFJ	B2L11_HUMAN	Gene/Protein Processing	[15]
Broad substrate specificity ATP-binding cassette transporter ABCG2 (ABCG2)	OTW8V2V1	ABCG2_HUMAN	Gene/Protein Processing	[16]
Caspase-3 (CASP3)	OTIJRBE7	CASP3_HUMAN	Gene/Protein Processing	[17]
Caspase-9 (CASP9)	OTD4RFFG	CASP9_HUMAN	Protein Interaction/Cellular Processes	[18]
Clusterin (CLU)	OTQGG0JM	CLUS_HUMAN	Gene/Protein Processing	[14]
Cyclin-A2 (CCNA2)	OTPHHYZJ	CCNA2_HUMAN	Gene/Protein Processing	[17]
Cyclin-dependent kinase inhibitor 1 (CDKN1A)	OTQWHCZE	CDN1A_HUMAN	Gene/Protein Processing	[19]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease

Cutaneous T-cell lymphoma

ICD Disease Classification

2B01

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Histone deacetylase 1 (HDAC1)	DTT	HDAC1	1.91E-11	0.44	1.3
P-glycoprotein 1 (ABCB1)	DTP	P-GP	5.54E-01	1.87E-01	4.30E-01
Organic anion transporting polypeptide 1B3 (SLCO1B3)	DTP	OATP1B3	1.48E-59	-3.95E+00	-5.81E+00
Cytochrome P450 2B6 (CYP2B6)	DME	CYP2B6	2.38E-13	-2.40E+00	-1.69E+00
Cytochrome P450 3A5 (CYP3A5)	DME	CYP3A5	4.87E-05	-5.90E-01	-7.24E-01
Cytochrome P450 3A4 (CYP3A4)	DME	CYP3A4	1.02E-14	-3.12E+00	-2.25E+00

Molecular Expression Atlas (MEA)

MEA Detail

Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Romidepsin (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Sarecycline	DMLZNIQ	Moderate	Decreased clearance of Romidepsin due to the transporter inhibition by Sarecycline .	Acne vulgaris [ED80]	[20]
Ivosidenib	DM8S6T7	Major	Increased risk of prolong QT interval by the combination of Romidepsin and Ivosidenib.	Acute myeloid leukaemia [2A60]	[21]
Midostaurin	DMI6E0R	Moderate	Increased risk of prolong QT interval by the combination of Romidepsin and Midostaurin.	Acute myeloid leukaemia [2A60]	[22]
Arn-509	DMT81LZ	Moderate	Increased metabolism of Romidepsin caused by Arn-509 mediated induction of CYP450 enzyme.	Acute myeloid leukaemia [2A60]	[20]
Gilteritinib	DMTI0ZO	Moderate	Increased risk of prolong QT interval by the combination of Romidepsin and Gilteritinib.	Acute myeloid leukaemia [2A60]	[23]
Oliceridine	DM6MDCF	Moderate	Increased risk of prolong QT interval by the combination of Romidepsin and Oliceridine.	Acute pain [MG31]	[24]
Ivabradine	DM0L594	Major	Increased risk of ventricular arrhythmias by the combination of Romidepsin and Ivabradine.	Angina pectoris [BA40]	[25]
Bedaquiline	DM3906J	Major	Increased risk of prolong QT interval by the combination of Romidepsin and Bedaquiline.	Antimicrobial drug resistance [MG50-MG52]	[26]
Levalbuterol	DM5YBO1	Moderate	Increased risk of prolong QT interval by the combination of Romidepsin and Levalbuterol.	Asthma [CA23]	[27]
Troleandomycin	DMUZNIG	Moderate	Decreased metabolism of Romidepsin caused by Troleandomycin mediated inhibition of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[20]
Erdafitinib	DMI782S	Moderate	Decreased clearance of Romidepsin due to the transporter inhibition by Erdafitinib.	Bladder cancer [2C94]	[28]
Pexidartinib	DMS2J0Z	Moderate	Increased metabolism of Romidepsin caused by Pexidartinib mediated induction of CYP450 enzyme.	Bone/articular cartilage neoplasm [2F7B]	[29]
Eribulin	DM1DX4Q	Moderate	Increased risk of prolong QT interval by the combination of Romidepsin and Eribulin.	Breast cancer [2C60-2C6Y]	[22]
Tucatinib	DMBESUA	Moderate	Decreased metabolism of Romidepsin caused by Tucatinib mediated inhibition of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[20]
Alpelisib	DMEXMYK	Moderate	Decreased clearance of Romidepsin due to the transporter inhibition by Alpelisib.	Breast cancer [2C60-2C6Y]	[20]
PF-04449913	DMSB068	Moderate	Increased risk of prolong QT interval by the combination of Romidepsin and PF-04449913.	Chronic myelomonocytic leukaemia [2A40]	[30]
Olodaterol	DM62B78	Moderate	Increased risk of prolong QT interval by the combination of Romidepsin and Olodaterol.	Chronic obstructive pulmonary disease [CA22]	[31]
Vilanterol	DMF5EK1	Moderate	Increased risk of prolong QT interval by the combination of Romidepsin and Vilanterol.	Chronic obstructive pulmonary disease [CA22]	[27]
Regorafenib	DMHSY1I	Moderate	Decreased clearance of Romidepsin due to the transporter inhibition by Regorafenib.	Colorectal cancer [2B91]	[20]
Ulipristal	DMBNI20	Moderate	Decreased clearance of Romidepsin due to the transporter inhibition by Ulipristal.	Contraceptive management [QA21]	[20]
Pasireotide	DMHM7JS	Major	Increased risk of prolong QT interval by the combination of Romidepsin and Pasireotide.	Cushing syndrome [5A70]	[22]
Osilodrostat	DMIJC9X	Moderate	Increased risk of prolong QT interval by the combination of Romidepsin and Osilodrostat.	Cushing syndrome [5A70]	[21]
Lumacaftor	DMCLWDJ	Moderate	Increased metabolism of Romidepsin caused by Lumacaftor mediated induction of CYP450 enzyme.	Cystic fibrosis [CA25]	[32]
Ivacaftor	DMZC1HS	Moderate	Decreased clearance of Romidepsin due to the transporter inhibition by Ivacaftor.	Cystic fibrosis [CA25]	[20]
Deutetrabenazine	DMUPFLI	Moderate	Additive CNS depression effects by the combination of Romidepsin and Deutetrabenazine.	Dystonic disorder [8A02]	[33]
Ingrezza	DMVPLNC	Moderate	Additive CNS depression effects by the combination of Romidepsin and Ingrezza.	Dystonic disorder [8A02]	[34]
Stiripentol	DMMSDOY	Moderate	Decreased metabolism of Romidepsin caused by Stiripentol mediated inhibition of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[35]
Boceprevir	DMBSHMF	Moderate	Decreased metabolism of Romidepsin caused by Boceprevir mediated inhibition of CYP450 enzyme.	Hepatitis virus infection [1E50-1E51]	[20]
Daclatasvir	DMSFK9V	Moderate	Decreased clearance of Romidepsin due to the transporter inhibition by Daclatasvir.	Hepatitis virus infection [1E50-1E51]	[20]
Fostemsavir	DM50ILT	Moderate	Increased risk of prolong QT interval by the combination of Romidepsin and Fostemsavir.	Human immunodeficiency virus disease [1C60-1C62]	[36]
Cobicistat	DM6L4H2	Moderate	Decreased metabolism of Romidepsin caused by Cobicistat mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[20]
Rilpivirine	DMJ0QOW	Moderate	Increased risk of prolong QT interval by the combination of Romidepsin and Rilpivirine.	Human immunodeficiency virus disease [1C60-1C62]	[22]
Teriflunomide	DMQ2FKJ	Major	Additive myelosuppressive effects by the combination of Romidepsin and Teriflunomide.	Hyper-lipoproteinaemia [5C80]	[37]
BMS-201038	DMQTAGO	Moderate	Decreased clearance of Romidepsin due to the transporter inhibition by BMS-201038.	Hyper-lipoproteinaemia [5C80]	[20]
Tolvaptan	DMIWFRL	Moderate	Decreased clearance of Romidepsin due to the transporter inhibition by Tolvaptan.	Hypo-osmolality/hyponatraemia [5C72]	[20]
Polyethylene glycol	DM4I1JP	Moderate	Increased risk of ventricular arrhythmias by the combination of Romidepsin and Polyethylene glycol.	Irritable bowel syndrome [DD91]	[25]
Denosumab	DMNI0KO	Moderate	Additive myelosuppressive effects by the combination of Romidepsin and Denosumab.	Low bone mass disorder [FB83]	[38]
Crizotinib	DM4F29C	Major	Increased risk of prolong QT interval by the combination of Romidepsin and Crizotinib.	Lung cancer [2C25]	[39]
Brigatinib	DM7W94S	Moderate	Increased metabolism of Romidepsin caused by Brigatinib mediated induction of CYP450 enzyme.	Lung cancer [2C25]	[40]
Ceritinib	DMB920Z	Major	Increased risk of prolong QT interval by the combination of Romidepsin and Ceritinib.	Lung cancer [2C25]	[22]
PF-06463922	DMKM7EW	Moderate	Increased metabolism of Romidepsin caused by PF-06463922 mediated induction of CYP450 enzyme.	Lung cancer [2C25]	[41]
Osimertinib	DMRJLAT	Major	Increased risk of prolong QT interval by the combination of Romidepsin and Osimertinib.	Lung cancer [2C25]	[42]
Capmatinib	DMYCXKL	Moderate	Decreased clearance of Romidepsin due to the transporter inhibition by Capmatinib.	Lung cancer [2C25]	[20]
Selpercatinib	DMZR15V	Major	Increased risk of prolong QT interval by the combination of Romidepsin and Selpercatinib.	Lung cancer [2C25]	[43]
Lumefantrine	DM29GAD	Major	Increased risk of prolong QT interval by the combination of Romidepsin and Lumefantrine.	Malaria [1F40-1F45]	[44]
IPI-145	DMWA24P	Moderate	Decreased metabolism of Romidepsin caused by IPI-145 mediated inhibition of CYP450 enzyme.	Mature B-cell leukaemia [2A82]	[45]
Ponatinib	DMYGJQO	Moderate	Decreased clearance of Romidepsin due to the transporter inhibition by Ponatinib.	Mature B-cell lymphoma [2A85]	[20]
Vemurafenib	DM62UG5	Major	Increased risk of prolong QT interval by the combination of Romidepsin and Vemurafenib.	Melanoma [2C30]	[22]
LGX818	DMNQXV8	Moderate	Increased risk of prolong QT interval by the combination of Romidepsin and LGX818.	Melanoma [2C30]	[46]
Dabrafenib	DMX6OE3	Moderate	Increased metabolism of Romidepsin caused by Dabrafenib mediated induction of CYP450 enzyme.	Melanoma [2C30]	[25]
Lasmiditan	DMXLVDT	Moderate	Decreased clearance of Romidepsin due to the transporter inhibition by Lasmiditan.	Migraine [8A80]	[47]
Panobinostat	DM58WKG	Major	Increased risk of prolong QT interval by the combination of Romidepsin and Panobinostat.	Multiple myeloma [2A83]	[48]
Tecfidera	DM2OVDT	Moderate	Additive immunosuppressive effects by the combination of Romidepsin and Tecfidera.	Multiple sclerosis [8A40]	[49]
Siponimod	DM2R86O	Major	Increased risk of ventricular arrhythmias by the combination of Romidepsin and Siponimod.	Multiple sclerosis [8A40]	[44]
Fingolimod	DM5JVAN	Major	Additive immunosuppressive effects by the combination of Romidepsin and Fingolimod.	Multiple sclerosis [8A40]	[50]
Ocrelizumab	DMEZ2KH	Moderate	Additive immunosuppressive effects by the combination of Romidepsin and Ocrelizumab.	Multiple sclerosis [8A40]	[51]
Ozanimod	DMT6AM2	Major	Increased risk of ventricular arrhythmias by the combination of Romidepsin and Ozanimod.	Multiple sclerosis [8A40]	[25]
Fedratinib	DM4ZBK6	Moderate	Decreased metabolism of Romidepsin caused by Fedratinib mediated inhibition of CYP450 enzyme.	Myeloproliferative neoplasm [2A20]	[25]
Rolapitant	DM8XP26	Moderate	Decreased clearance of Romidepsin due to the transporter inhibition by Rolapitant.	Nausea/vomiting [MD90]	[20]
Entrectinib	DMMPTLH	Moderate	Increased risk of prolong QT interval by the combination of Romidepsin and Entrectinib.	Non-small cell lung cancer [2C25]	[25]
Rucaparib	DM9PVX8	Moderate	Increased risk of prolong QT interval by the combination of Romidepsin and Rucaparib.	Ovarian cancer [2C73]	[22]
Triclabendazole	DMPWGBR	Moderate	Increased risk of prolong QT interval by the combination of Romidepsin and Triclabendazole.	Parasitic worm infestation [1F90]	[24]
Istradefylline	DM20VSK	Moderate	Decreased clearance of Romidepsin due to the transporter inhibition by Istradefylline.	Parkinsonism [8A00]	[20]
Abametapir	DM2RX0I	Moderate	Decreased metabolism of Romidepsin caused by Abametapir mediated inhibition of CYP450 enzyme.	Pediculosis [1G00]	[52]
Macimorelin	DMQYJIR	Major	Increased risk of prolong QT interval by the combination of Romidepsin and Macimorelin.	Pituitary gland disorder [5A60-5A61]	[53]
Lefamulin	DME6G97	Major	Increased risk of prolong QT interval by the combination of Romidepsin and Lefamulin.	Pneumonia [CA40]	[21]
Lonafarnib	DMGM2Z6	Moderate	Decreased metabolism of Romidepsin caused by Lonafarnib mediated inhibition of CYP450 enzyme.	Premature ageing appearance [LD2B]	[20]
Degarelix	DM3O8QY	Moderate	Increased risk of prolong QT interval by the combination of Romidepsin and Degarelix.	Prostate cancer [2C82]	[25]
Enzalutamide	DMGL19D	Moderate	Increased metabolism of Romidepsin caused by Enzalutamide mediated induction of CYP450 enzyme.	Prostate cancer [2C82]	[20]
Relugolix	DMK7IWL	Moderate	Increased risk of prolong QT interval by the combination of Romidepsin and Relugolix.	Prostate cancer [2C82]	[25]
Rilonacept	DMGLUQS	Moderate	Additive immunosuppressive effects by the combination of Romidepsin and Rilonacept.	Rheumatoid arthritis [FA20]	[54]
Golimumab	DMHZV7X	Major	Additive immunosuppressive effects by the combination of Romidepsin and Golimumab.	Rheumatoid arthritis [FA20]	[55]
Amisulpride	DMSJVAM	Major	Increased risk of prolong QT interval by the combination of Romidepsin and Amisulpride.	Schizophrenia [6A20]	[56]
Asenapine	DMSQZE2	Moderate	Increased risk of prolong QT interval by the combination of Romidepsin and Asenapine.	Schizophrenia [6A20]	[22]
Anthrax vaccine	DM9GSWY	Moderate	Antagonize the effect of Romidepsin when combined with Anthrax vaccine.	Sepsis [1G40-1G41]	[57]
Telotristat ethyl	DMDIYFZ	Moderate	Increased metabolism of Romidepsin caused by Telotristat ethyl mediated induction of CYP450 enzyme.	Small intestine developmental anomaly [DA90]	[25]
Larotrectinib	DM26CQR	Moderate	Decreased metabolism of Romidepsin caused by Larotrectinib mediated inhibition of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[44]
LEE011	DMMX75K	Major	Decreased metabolism of Romidepsin caused by LEE011 mediated inhibition of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[22]
Triptorelin	DMTK4LS	Moderate	Increased risk of prolong QT interval by the combination of Romidepsin and Triptorelin.	Solid tumour/cancer [2A00-2F9Z]	[25]
Pitolisant	DM8RFNJ	Moderate	Increased risk of prolong QT interval by the combination of Romidepsin and Pitolisant.	Somnolence [MG42]	[22]
Telavancin	DM58VQX	Moderate	Increased risk of prolong QT interval by the combination of Romidepsin and Telavancin.	Staphylococcal/streptococcal disease [1B5Y]	[22]
Fostamatinib	DM6AUHV	Moderate	Decreased clearance of Romidepsin due to the transporter inhibition by Fostamatinib.	Thrombocytopenia [3B64]	[58]
Lenvatinib	DMB1IU4	Moderate	Increased risk of prolong QT interval by the combination of Romidepsin and Lenvatinib.	Thyroid cancer [2D10]	[22]
Cabozantinib	DMIYDT4	Major	Increased risk of prolong QT interval by the combination of Romidepsin and Cabozantinib.	Thyroid cancer [2D10]	[25]
-----------


⏷ Show the Full List of 84 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG

DIG Name	DIG ID	PubChem CID	Functional Classification
DL-alpha-tocopherol	E00052	2116	Antioxidant
Ethanol	E00023	702	Antimicrobial preservative; Penetration agent; Solvent
Povidone	E00667	Not Available	Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
Propylene glycol	E00040	1030	Antimicrobial preservative; Humectant; Plasticizing agent; Solvent
--------------------

Pharmaceutical Formulation

Formulation Name	Drug Dosage	Dosage Form	Route
Romidepsin 10mg/2ml solution	10mg/2ml	Solution	Intravenous
Romidepsin 27.5mg/5.5ml solution	27.5mg/5.5ml	Solution	Intravenous
Romidepsin 10mg/vial powder	10mg/vial	Powder	Intravenous

Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7006).
2	Romidepsin FDA Label
3	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4	BDDCS applied to over 900 drugs
5	Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
6	Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
7	Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.
8	Population pharmacokinetics of romidepsin in patients with cutaneous T-cell lymphoma and relapsed peripheral T-cell lymphoma. Clin Cancer Res. 2009 Feb 15;15(4):1496-503.
9	A phase I/II trial of the histone deacetylase inhibitor romidepsin for adults with recurrent malignant glioma: North American Brain Tumor Consortium Study 03-03. Neuro Oncol. 2011 May;13(5):509-16.
10	Population pharmacokinetics of romidepsin in patients with cutaneous T-cell lymphoma and relapsed peripheral T-cell lymphoma. Clin Cancer Res. 2009 Feb 15;15(4):1496-503.
11	FDA Label of Romidepsin. The 2020 official website of the U.S. Food and Drug Administration.
12	Chemoresistance to depsipeptide FK228 [(E)-(1S,4S,10S,21R)-7-[(Z)-ethylidene]-4,21-diisopropyl-2-oxa-12,13-dithia-5,8,20,23-tetraazabicyclo[8,7,6]-tricos-16-ene-3,6,9,22-pentanone] is mediated by reversible MDR1 induction in human cancer cell lines. J Pharmacol Exp Ther. 2005 Jul;314(1):467-75. doi: 10.1124/jpet.105.083956. Epub 2005 Apr 15.
13	Blocking downstream signaling pathways in the context of HDAC inhibition promotes apoptosis preferentially in cells harboring mutant Ras. Oncotarget. 2016 Oct 25;7(43):69804-69815. doi: 10.18632/oncotarget.12001.
14	5-Aza-2'-deoxycytidine and depsipeptide synergistically induce expression of BIK (BCL2-interacting killer). Biochem Biophys Res Commun. 2006 Dec 15;351(2):455-61. doi: 10.1016/j.bbrc.2006.10.055. Epub 2006 Oct 18.
15	Histone deacetylase inhibitors FK228, N-(2-aminophenyl)-4-[N-(pyridin-3-yl-methoxycarbonyl)amino- methyl]benzamide and m-carboxycinnamic acid bis-hydroxamide augment radiation-induced cell death in gastrointestinal adenocarcinoma cells. Int J Cancer. 2004 Jun 10;110(2):301-8. doi: 10.1002/ijc.20117.
16	Aberrant promoter methylation of the ABCG2 gene in renal carcinoma. Mol Cell Biol. 2006 Nov;26(22):8572-85.
17	Abrogation of p21 expression by flavopiridol enhances depsipeptide-mediated apoptosis in malignant pleural mesothelioma cells. Clin Cancer Res. 2004 Mar 1;10(5):1813-25. doi: 10.1158/1078-0432.ccr-0901-3.
18	Interactions between bortezomib and romidepsin and belinostat in chronic lymphocytic leukemia cells. Clin Cancer Res. 2008 Jan 15;14(2):549-58. doi: 10.1158/1078-0432.CCR-07-1934.
19	Up-regulation of MDR1 and induction of doxorubicin resistance by histone deacetylase inhibitor depsipeptide (FK228) and ATRA in acute promyelocytic leukemia cells. Blood. 2006 Feb 15;107(4):1546-54. doi: 10.1182/blood-2004-10-4126. Epub 2005 Oct 13.
20	Product Information. Istodax (romidepsin). Gloucester Pharmaceuticals, Cambridge, MA.
21	Product Information. Fycompa (perampanel). Eisai Inc, Teaneck, NJ.
22	Canadian Pharmacists Association.
23	Product Information. Xospata (gilteritinib). Astellas Pharma US, Inc, Deerfield, IL.
24	Iannini PB "Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval." Expert Opin Drug Saf 1 (2002): 121-8. [PMID: 12904146]
25	Cerner Multum, Inc. "UK Summary of Product Characteristics.".
26	Product Information. Sirturo (bedaquiline). Janssen Pharmaceuticals, Titusville, NJ.
27	Product Information. Arcapta Neohaler (indacaterol). Novartis Pharmaceuticals, East Hanover, NJ.
28	Product Information. Balversa (erdafitinib). Janssen Products, LP, Horsham, PA.
29	Product Information. Sonata (zaleplon) Wyeth-Ayerst Laboratories, Philadelphia, PA.
30	Product Information. Daurismo (glasdegib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
31	Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982): 726-32. [PMID: 7042176]
32	Patel S, Robinson R, Burk M "Hypertensive crisis associated with St. John's Wort." Am J Med 112 (2002): 507-8. [PMID: 11959071]
33	Product Information. Austedo (deutetrabenazine). Teva Pharmaceuticals USA, North Wales, PA.
34	Product Information. Ingrezza (valbenazine). Neurocrine Biosciences, Inc., San Diego, CA.
35	EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports.".
36	Product Information. Rukobia (fostemsavir). ViiV Healthcare, Research Triangle Park, NC.
37	Product Information. Arava (leflunomide). Hoechst Marion-Roussel Inc, Kansas City, MO.
38	Product Information. Prolia (denosumab). Amgen USA, Thousand Oaks, CA.
39	Product Information. Xalkori (crizotinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
40	Product Information. Alunbrig (brigatinib). Ariad Pharmaceuticals Inc, Cambridge, MA.
41	Product Information. Lorbrena (lorlatinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
42	Product Information. Tagrisso (osimertinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
43	Product Information. Retevmo (selpercatinib). Lilly, Eli and Company, Indianapolis, IN.
44	Cerner Multum, Inc. "Australian Product Information.".
45	Product Information. Copiktra (duvelisib). Verastem, Inc., Needham, MA.
46	Product Information. Braftovi (encorafenib). Array BioPharma Inc., Boulder, CO.
47	Product Information. Reyvow (lasmiditan). Lilly, Eli and Company, Indianapolis, IN.
48	Product Information. Farydak (panobinostat). Novartis Pharmaceuticals, East Hanover, NJ.
49	Product Information. Vumerity (diroximel fumarate). Alkermes, Inc, Cambridge, MA.
50	Product Information. Gilenya (fingolimod). Novartis Pharmaceuticals, East Hanover, NJ.
51	Product Information. Ocrevus (ocrelizumab). Genentech, South San Francisco, CA.
52	Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
53	Product Information. Macrilen (macimorelin). Aeterna Zentaris, Charleston, SC.
54	Product Information. Arcalyst (rilonacept). Regeneron Pharmaceuticals Inc, Tarrytown, NY.
55	Product Information. Cimzia (certolizumab). UCB Pharma Inc, Smyrna, GA.
56	Product Information. Barhemsys (amisulpride). Acacia Pharma, Inc, Indianapolis, IN.
57	CDC. Centers for Disease Control and Prevention/ "Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence." MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18. [PMID: 20300058]
58	Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.